RespirERA is organizing the 6th Joint Meeting on Lung Cancer on October 14–15, 2027, in Nice, France. Dedicated to innovative therapeutic molecules and predictive biomarkers, this international meeting builds on an ongoing scientific collaboration with MD Anderson Cancer Center.
Two days dedicated to precision medicine in lung cancer
Under the title “Innovative Drug Molecules & Predictive Biomarkers”, this sixth edition will bring together clinicians, researchers, pathologists, and biologists to discuss developments in lung cancer care.
The program will explore two complementary aspects of precision medicine. The first is the development of new molecules and therapeutic strategies. The second is the identification of predictive biomarkers, biological characteristics studied to help anticipate treatment response and guide therapeutic decisions.
Discussions will connect research and clinical practice, with a particular focus on mechanisms of resistance and opportunities to personalize treatment.
From therapeutic innovations to new approaches to biomarkers
The first day will cover immunotherapy, antibody-drug conjugates, and targeted therapies. Presentations will also address residual disease, brain metastases, and the mechanisms through which cancer cells adapt to treatment.
The second day will place particular emphasis on artificial intelligence and digital pathology, which involves analyzing digitized tissue images. Experts will present approaches combining imaging and molecular data, alongside research on digital twins and liquid biopsy.
Several presentations will focus on the molecular characteristics of tumors, including those involving KRAS, EGFR, HER2, or MTAP loss, and their implications for the development of tailored treatments.
Bringing together international experts and RespirERA teams
The program features specialists from European and American institutions, including MD Anderson Cancer Center, Gustave Roussy, Lausanne University Hospital (CHUV), Heidelberg University, Brown University, and Moffitt Cancer Center.
Solange Peters, John V. Heymach, Ignacio Wistuba, Sandurai A. Mani, Mihaela Aldea, Albrecht Stenzinger, and David Planchard are among the announced speakers.
RespirERA Institute teams will contribute to several sessions. Jean Albrengues will discuss research on neutrophils and resistance to immunotherapy. Guylène Rignol will present an integrative pathology strategy for cancers harboring KRAS mutations. Hervé Delingette will address biomarker extraction from multiple types of data, while Paul Hofman will present the institute’s multimodal artificial intelligence approaches in precision oncology.
Attend the 6th Joint Meeting on Lung Cancer
The meeting is intended for healthcare professionals, researchers, pathologists, biologists, students, and professionals involved in healthcare innovation with an interest in lung cancer and precision medicine.
If you are a member of the RespirERA Institute, please contact us at contact@ihu-respirera.fr !
Français 
English (UK) 